The TRIMEDX Clinical Asset Management (CAM) Advanced solution assists healthcare leaders in navigating the complex challenge of managing costs and growing service lines. Through the use of the proprietary TRIMEDX RUDR Score, a personalized, fact-based algorithm that supports clinical asset replacement, upgrade, disposition and reallocation strategies, TRIMEDX leads health systems in improving the financial health of their organization by extending the useful life and optimizing utilization of their existing clinical asset inventory. The TRIMEDX RUDR Score methodology analyzes data on over 4.2M clinical assets to assess and score each clinical asset based on: • Cybersecurity risk • Medical device utilization • Years of remaining useful life • Parts availability • Device criticality • Documented repair events • Equipment downtime In addition, our Clinical Asset Informatics platform provides visibility to proprietary, national benchmarks to help elevate asset optimization decisions and maximize return on investment.

As the largest independent, technology-enabled clinical asset management company in the United States, TRIMEDX provides strategic planning and management of clinical assets to drive operational cost savings, free up capital for new strategic initiatives and deliver improved risk management and cyber protection.

Invaryant connects to all leading EMR/EHR systems, wearables, internet of medical things, and telehealth and remote monitoring. With patient permission, retrieve your patients' health and medical information wherever it exists (e.g., different EMR systems).

Invaryant is a Georgia-based health tech company enabling safer healthcare through integrated, real-world data and patented technologies. Our platform connects patients with those who make healthy possible, creating a secure, real-time, inter- & extraoperable environment for patient safety. Who benefits from Invaryant? • Patients • Physicians and other providers (in-person and telehealth) • Researchers • Patient safety programs (such as REMS and pharmacovigilance)